找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Current Advances in Osteosarcoma; Eugenie S. Kleinerman, M.D. Book 20141st edition Springer Nature Switzerland AG 2014 bone cancer.cancer.

[复制链接]
楼主: nourish
发表于 2025-3-23 13:41:52 | 显示全部楼层
Oncolytic Viruses for Potential Osteosarcoma Therapy specific and replication competent viruses. Osteosarcoma is a challenging malignancy to identify novel targets for therapy due to its complex genetic make-up. Oncolytic virotherapy may be a promising approach as a novel therapeutic, not dependent on consistent expression of a single target. In this
发表于 2025-3-23 17:49:09 | 显示全部楼层
发表于 2025-3-23 20:34:17 | 显示全部楼层
发表于 2025-3-24 00:08:31 | 显示全部楼层
发表于 2025-3-24 06:11:12 | 显示全部楼层
Worship Spaces: 1001–2000 Seatse then validated using independent validation experiments. From these results, we identified four RTKs (Axl, EphB2, FGFR2, and Ret) that have not been previously studied in osteosarcoma and provide targets for the development of novel therapeutics.
发表于 2025-3-24 07:27:02 | 显示全部楼层
https://doi.org/10.1007/978-1-4939-3097-5ls and pericytes, are the major source of Notch activation in osteosarcoma tumors in vivo and in patients. As a result, Notch pathway expression is not expected to be uniform across a tumor but likely to be highest in those areas immediately adjacent to blood vessels. Therapeutic targeting of the No
发表于 2025-3-24 12:54:34 | 显示全部楼层
发表于 2025-3-24 17:59:09 | 显示全部楼层
Jarno Drost,Benedetta Artegiani,Hans Clevers sensitivity to GCB in LM7 cells. By contrast, inhibiting autophagy in K7M3 cells decreased GCB sensitivity. Defining the role autophagy plays in chemotherapy response in different tumor types has become of greater importance in order to identify the best suitable therapeutic approach. In this chapt
发表于 2025-3-24 22:41:08 | 显示全部楼层
发表于 2025-3-25 01:04:45 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-1 21:04
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表